LILRB2 and neoplasm: A recent study by Chen et al. [90] showed that activated EGFR-signaling induced ILT4 overexpression in NSCLC cells via the ERK1/2 and AKT signaling pathways and suppressed tumor immunity by recruiting M2-like TAMs, diminishing the T-cell response.